Tags

Type your tag names separated by a space and hit enter

Human papillomavirus and vaccination in cervical cancer.
Taiwan J Obstet Gynecol 2007; 46(4):352-62TJ

Abstract

Cervical cancer is not only the most frequently reported cancer among women, but also the most common female genital tract neoplasm in Taiwan. Early detection is effective, because the development, maintenance and progression of precursor lesions (cervical intraepithelial neoplasia [CIN]) evolve slowly into invasive cancer, typically over a period of more than 10 years. It is now recognized that human papillomavirus (HPV) infection is a necessary cause for over 99% of cervical cancer cases. Advances in the understanding of the causative role of HPV in the etiology of high-grade cervical lesions (CIN 2/3) and cervical cancer have led to the development, evaluation and recommendation of HPV-based technologies for cervical cancer prevention and control. The prevention of HPV infection before the onset of CIN is now possible with recently available prophylactic HPV vaccines, e.g. the quadrivalent Gardasil (Merck & Co., NJ, USA) and bivalent Cervarix (GlaxoSmithKline, London, UK). This review article provides an up-to-date summary of recent studies and available information concerning HPV and vaccination in cervical cancer.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Mackay Memorial Hospital, National Taipei College of Nursing, Taipei, Taiwan. kl421229@ms6.hinet.net

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18182340

Citation

Wang, Kung-Liahng. "Human Papillomavirus and Vaccination in Cervical Cancer." Taiwanese Journal of Obstetrics & Gynecology, vol. 46, no. 4, 2007, pp. 352-62.
Wang KL. Human papillomavirus and vaccination in cervical cancer. Taiwan J Obstet Gynecol. 2007;46(4):352-62.
Wang, K. L. (2007). Human papillomavirus and vaccination in cervical cancer. Taiwanese Journal of Obstetrics & Gynecology, 46(4), pp. 352-62. doi:10.1016/S1028-4559(08)60004-2.
Wang KL. Human Papillomavirus and Vaccination in Cervical Cancer. Taiwan J Obstet Gynecol. 2007;46(4):352-62. PubMed PMID: 18182340.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Human papillomavirus and vaccination in cervical cancer. A1 - Wang,Kung-Liahng, PY - 2008/1/10/pubmed PY - 2008/2/5/medline PY - 2008/1/10/entrez SP - 352 EP - 62 JF - Taiwanese journal of obstetrics & gynecology JO - Taiwan J Obstet Gynecol VL - 46 IS - 4 N2 - Cervical cancer is not only the most frequently reported cancer among women, but also the most common female genital tract neoplasm in Taiwan. Early detection is effective, because the development, maintenance and progression of precursor lesions (cervical intraepithelial neoplasia [CIN]) evolve slowly into invasive cancer, typically over a period of more than 10 years. It is now recognized that human papillomavirus (HPV) infection is a necessary cause for over 99% of cervical cancer cases. Advances in the understanding of the causative role of HPV in the etiology of high-grade cervical lesions (CIN 2/3) and cervical cancer have led to the development, evaluation and recommendation of HPV-based technologies for cervical cancer prevention and control. The prevention of HPV infection before the onset of CIN is now possible with recently available prophylactic HPV vaccines, e.g. the quadrivalent Gardasil (Merck & Co., NJ, USA) and bivalent Cervarix (GlaxoSmithKline, London, UK). This review article provides an up-to-date summary of recent studies and available information concerning HPV and vaccination in cervical cancer. SN - 1875-6263 UR - https://www.unboundmedicine.com/medline/citation/18182340/Human_papillomavirus_and_vaccination_in_cervical_cancer_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1028-4559(08)60004-2 DB - PRIME DP - Unbound Medicine ER -